Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure

International Journal of Clinical Practice

Volumn 65, Issue 8, 2011, Pages 911-

  Meredith, P A ^a   Jarvis, S C ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Richford Gate Medical Practice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; RAMIPRIL;

CARDIOVASCULAR DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIASTOLIC BLOOD PRESSURE; HEALTH CARE COST; HEALTH SURVEY; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; LETTER; LONG TERM CARE; MORTALITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC);

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; LOSARTAN; MALE; TETRAZOLES;

EID: 79960509350     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02700.x     Document Type: Letter

References (10)

1. Grosso AM, Bodalia PN, MacAllister RJ, Hingorani AD, Moon JC, Scott MA,. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review. Int J Clin Pract 2011. doi
2. Minhas R,. Waste not, want not: free money, moral hazard and value-based prescribing. Int J Clin Pract 2011. doi
3. Pitt B, Julius S,. Easy money?: health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class. Int J Clin Pract 2011. doi
4. Meredith PA, McInnes GT, Murray LS,. Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension. J Hum Hypertens 2010; 24: 525-31.
5. Health Survey for England. Cardiovascular Disease and Risk Factors in Adults. Available at:. 2006
6. Kjeldsen SE, Stalhammar J, Hasvold P, Bodegard J, Olsson U, Russell D,. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 2010; 24: 263-73.
7. Henriksson M, Russell D, Bodegard J, et al., Health-care costs of losartan and candesartan in the primary treatment of hypertension. J Hum Hypertens 2010; 25: 130-6.
8. Eklind-Cervenka M, Benson L, Dahlström U, Edner M, Rosenqvist M, Lund LH,. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011; 305: 175-82.
9. Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M,. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract 2007; 61: 15-23.
10. Prescription Cost Analysis England. Available at:. 2009.